Cerebral Therapeutics, a clinical-stage pharmaceutical company developing specialty medications for uncontrolled neurological diseases, announced yesterday that it has named Lisa Shafer, PhD as its new chief scientific officer, and Eric Distad as vice president of clinical development.
Dr Shafer's technical and leadership experience in R&D, strategy, product and business development includes the medical device, biotechnology and pharmaceutical industries. Prior to her experience in the pharmaceutical industry, Dr Shafer spent more than 10 years in the medical device industry. While at Medtronic Inc, Dr Shafer held various roles in neuromodulation research, drug-device combination product development, and management. Dr Shafer's foundational research and leadership resulted in seminal publications regarding mechanistic, proof-of-concept and clinical evidence for a portfolio of translational and clinical research programs to advance targeted drug-delivery to the central nervous system (CNS). She started her career at 3M in the Pharmaceutical and Drug Delivery Division.
Eric Distad, vice president of Clinical Development, has more than 24 years' experience in medical device and combination product clinical development. Prior to joining Cerebral Therapeutics, Distad's experience included Global Program Management at Medtronic in the Cardiac Rhythm Management and Neuromodulation Divisions, start-up and early commercial orthopaedic companies, and leadership roles at two large Clinical Research Organisations within their Global Medical Device and Combination Product Divisions. In addition, he has served in advisory positions for Medical Technology Angel Funding groups, International Medical Device and Combination Product Regulatory Panels and Therapeutic Advisory Panels.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference